-sertib
Drugs that block serine/threonine kinases.
- Drugs ending in -sertib: 67
- Approved somewhere: 1
- With a US drug page: 2
- Stem
- -sertib
- Class
- Drugs that block serine/threonine kinases
- Most common targets
- Serine/threonine-protein kinase AKT (6), Serine/threonine-protein kinase Aurora (4), ATR (3), PLK1 (3), MTOR (3), AURKB (2), Vascular endothelial growth factor receptor (2), WEE1 (2)
Approved and clinical-stage drugs in ChEMBL whose names ending in -sertib, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Capivasertib | Approved | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT inhibitor |
| Zilurgisertib | Phase 2 | — | — |
| Afuresertib | Phase 3 | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT inhibitor |
| Alisertib | Phase 3 | AURKA | Serine/threonine-protein kinase Aurora-A inhibitor |
| Ceralasertib | Phase 3 | ATR | Serine-protein kinase ATR inhibitor |
| Ibcasertib | Phase 3 | AURKB, Vascular endothelial growth factor receptor | Serine/threonine-protein kinase Aurora-B inhibitor |
| Ipatasertib | Phase 3 | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT inhibitor |
| Rigosertib | Phase 3 | — | — |
| Selonsertib | Phase 3 | MAP3K5 | Mitogen-activated protein kinase kinase kinase 5 inhibitor |
| Volasertib | Phase 3 | PLK1 | Serine/threonine-protein kinase PLK1 inhibitor |
| Adavosertib | Phase 2 | WEE1 | Serine/threonine-protein kinase WEE1 inhibitor |
| Amcasertib | Phase 2 | — | — |
| Azenosertib | Phase 2 | WEE1 | Serine/threonine-protein kinase WEE1 inhibitor |
| Barasertib | Phase 2 | AURKB | Serine/threonine-protein kinase Aurora-B inhibitor |
| Berzosertib | Phase 2 | ATR | Serine-protein kinase ATR inhibitor |
| Camonsertib | Phase 2 | — | — |
| Danusertib | Phase 2 | Serine/threonine-protein kinase Aurora | Serine/threonine-protein kinase Aurora inhibitor |
| Dapolsertib | Phase 2 | — | — |
| Darovasertib | Phase 2 | — | — |
| Defosbarasertib | Phase 2 | — | — |
| Delcasertib | Phase 2 | PRKCD | Protein kinase C delta inhibitor |
| Eclitasertib | Phase 2 | — | — |
| Edecesertib | Phase 2 | — | — |
| Fidrisertib | Phase 2 | — | — |
| Galunisertib | Phase 2 | TGFBR1 | TGF-beta receptor type I inhibitor |
| Ilorasertib | Phase 2 | Serine/threonine-protein kinase Aurora, Vascular endothelial growth factor receptor, SRC, PDGFRA, PDGFRB | Serine/threonine-protein kinase Aurora inhibitor |
| Inlexisertib | Phase 2 | — | — |
| Lartesertib | Phase 2 | — | — |
| Lunresertib | Phase 2 | — | — |
| Luvixasertib | Phase 2 | — | — |
| Miransertib | Phase 2 | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT inhibitor |
| Monzosertib | Phase 2 | — | — |
| Nuvisertib | Phase 2 | — | — |
| Ocifisertib | Phase 2 | PLK4 | Serine/threonine-protein kinase PLK4 inhibitor |
| Oditrasertib | Phase 2 | — | — |
| Onatasertib | Phase 2 | MTOR | Serine/threonine-protein kinase mTOR inhibitor |
| Onvansertib | Phase 2 | PLK1 | Serine/threonine-protein kinase PLK1 inhibitor |
| Padnarsertib | Phase 2 | — | — |
| Pifusertib | Phase 2 | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT negative allosteric modulator |
| Pimasertib | Phase 2 | MAP2K1, MAP2K2 | Dual specificity mitogen-activated protein kinase kinase 1 inhibitor |
| Plogosertib | Phase 2 | — | — |
| Potrasertib | Phase 2 | — | — |
| Prexasertib | Phase 2 | CHEK1, CHEK2 | Serine/threonine-protein kinase Chk1 inhibitor |
| Rabusertib | Phase 2 | CHEK1 | Serine/threonine-protein kinase Chk1 inhibitor |
| Rupitasertib | Phase 2 | AKT1, AKT3, RPS6KB1, RPS6KB2 | Serine/threonine-protein kinase AKT inhibitor |
| Sapanisertib | Phase 2 | MTOR | Serine/threonine-protein kinase mTOR inhibitor |
| Silmitasertib | Phase 2 | CSNK2A1 | Casein kinase II alpha inhibitor |
| Tanzisertib | Phase 2 | MAPK8, MAPK9, MAPK10 | c-Jun N-terminal kinase 1 inhibitor |
| Tilpisertib | Phase 2 | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 inhibitor |
| Tilpisertib fosmecarbil | Phase 2 | — | — |
| Tinodasertib | Phase 2 | — | — |
| Tomivosertib | Phase 2 | MKNK1, MKNK2 | MAP kinase-interacting serine/threonine-protein kinase 1/2 inhibitor |
| Tozasertib | Phase 2 | Serine/threonine-protein kinase Aurora | Serine/threonine-protein kinase Aurora inhibitor |
| Tuvusertib | Phase 2 | — | — |
| Uprosertib | Phase 2 | Serine/threonine-protein kinase AKT | Serine/threonine-protein kinase AKT inhibitor |
| Vactosertib | Phase 2 | TGFBR1 | TGF-beta receptor type I inhibitor |
| Vistusertib | Phase 2 | MTOR | Serine/threonine-protein kinase mTOR inhibitor |
| Zimlovisertib | Phase 2 | IRAK4 | Interleukin-1 receptor-associated kinase 4 inhibitor |
| Cafusertib | Phase 1 | PLK1 | Serine/threonine-protein kinase PLK1 inhibitor |
| Cenisertib | Phase 1 | Serine/threonine-protein kinase Aurora | Serine/threonine-protein kinase Aurora inhibitor |
| Elimusertib | Phase 1 | ATR | Serine-protein kinase ATR inhibitor |
| Emavusertib | Phase 1 | — | — |
| Flizasertib | Phase 1 | — | — |
| Nedisertib | Phase 1 | — | — |
| Ocadusertib | Phase 1 | — | — |
| Simurosertib | Phase 1 | CDC7 | Cell division cycle 7-related protein kinase inhibitor |
| Vevorisertib | Phase 1 | — | — |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO